Mga Batayang Estadistika
| CIK | 1710072 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Edgewise Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 7, 2025 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commiss |
|
| August 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 7, 2025 |
Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights – Announced positive top-line data from the open-label extension MESA trial of sevasemten in participants with Becker muscular dystrophy who previously completed ARCH and CANYON studies – – Announced encouraging top-line data from the Phase 2 LYNX and FOX trials of sevasemte |
|
| June 26, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 26, 2025 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| May 8, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 8, 2025 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commission |
|
| May 8, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 8, 2025 |
Exhibit 99.1 News Release Edgewise Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights – Announced positive top-line results from Phase 2 CIRRUS-HCM trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – – Strengthened balance sheet with net proceeds of approximately $188 million from the April 2025 public offering; pro-forma cash balance exceeds $624 million |
|
| May 8, 2025 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.1 OUTSIDE DIRECTOR COMPENSATION POLICY (as amended and restated March 20, 2025) Edgewise Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are not employees of the Company |
|
| April 29, 2025 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a party other than the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| April 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a party other than the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 2, 2025 |
Exhibit 99.1 News Release Edgewise Therapeutics Announces Positive Top-Line Results from Phase 2 CIRRUS-HCM Four-Week Trial of EDG-7500 in Hypertrophic Cardiomyopathy (HCM) – Phase 2 trial of EDG-7500 demonstrated rapid and clinically meaningful reductions in LVOT gradients in participants with obstructive HCM – – Four-week treatment with EDG-7500 demonstrated substantial improvements in measures |
|
| April 2, 2025 |
Filed Pursuant to Rule 424(b)(5) Registration No. 333-279299 Prospectus Supplement (To Prospectus Dated May 10, 2024) 9,935,419 Shares Common stock We are offering an aggregate of 9,935,419 shares of our common stock, par value $0.0001 per share. Our common stock is listed on the Nasdaq Global Select Market under the symbol “EWTX.” The last reported sale price of our common stock on April 1, 2025, |
|
| April 2, 2025 |
Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock Exhibit 99.1 News Release Edgewise Therapeutics Announces Pricing of $200 Million Underwritten Offering of Common Stock BOULDER, Colo., (April 2, 2025) - Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of $20.13 shares of its common stock at an offering price of $9,935,419 per share. Edgewise an |
|
| April 2, 2025 |
Underwriting Agreement between the Company and Leerink Partners LLC, dated as of April 2, 2025. Exhibit 1.1 UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. 9,935,419 Shares of Common Stock Underwriting Agreement April 2, 2025 Leerink Partners LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Leerink Partners LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Edgewise Therapeutics, Inc., a Delaware corporation (the “Com |
|
| April 2, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| April 2, 2025 |
Exhibit 99.2 1 EDG-7500: Phase 2 CIRRUS-HCM Development Program Update April 2, 2025 2 Forward Looking Statement This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this presentation that are not purely historical are forward-looking statements. Such forward- |
|
| April 2, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 2, 2025 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| April 2, 2025 |
Table 1: Newly Registered and Carry Forward Securities Calculation of Filing Fee Tables S-3 Edgewise Therapeutics, Inc. Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Carry Forward Form Type Carry Forward File Number Carry Forward Initial Effecti |
|
| March 3, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2025 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| March 3, 2025 |
Exhibit 19.1 EDGEWISE THERAPEUTICS, INC. INSIDER TRADING POLICY (As amended March 2, 2023) A.POLICY OVERVIEW Edgewise Therapeutics, Inc. (together with any subsidiaries, collectively the “Company”) has adopted this Insider Trading Policy (the “Policy”) to help you comply with the federal and state securities laws and regulations that govern trading in securities and to help the Company minimize it |
|
| March 3, 2025 |
Offer Letter between the Registrant and Robert Blaustein, M.D., Ph.D. Exhibit 10.20 December 14, 2024 Robert Blaustein, M.D., Ph.D. Re: Employment Offer Dear Dr. Blaustein, This will confirm the terms under which Edgewise Therapeutics, Inc. (the “Company”) has made you an offer of employment: 1. Position. You will serve as Chief Development Officer and shall perform such duties as are ordinary, customary and necessary in such role. You will report to the Chief Execu |
|
| March 3, 2025 |
As filed with the Securities and Exchange Commission on March 3, 2025 As filed with the Securities and Exchange Commission on March 3, 2025 Registration No. |
|
| March 3, 2025 |
Exhibit 99.1 News Release Edgewise Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights – Completed enrollment of the GRAND CANYON global pivotal study of sevasemten in Becker muscular dystrophy (Becker) – – Announced positive top-line results from Phase 2 CANYON trial of sevasemten in Becker – – On track to report data from Phase 2 CIRRUS-HCM tri |
|
| March 3, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exa |
|
| March 3, 2025 |
Calculation of Filing Fee Tables S-8 Edgewise Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common Stock, par value $0.0001 per share, reserved for issuance pursuant to the 2021 Employee Stock Purc |
|
| February 3, 2025 |
Exhibit 1 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended, the persons named below agree to the joint filing on behalf of each of them of a statement on Schedule 13G (including amendments thereto) with respect to the Common Stock, $0. |
|
| January 22, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2025 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commis |
|
| December 16, 2024 |
Regulation FD Disclosure, Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Comm |
|
| December 16, 2024 |
Exhibit 99.2 1 ©2024 Edgewise Therapeutics. All rights reserved. Sevasemten: Topline Results from the CANYON Phase 2 Trial in Becker December 16, 2024 2 This presentation contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this presentation that are not purely historical are f |
|
| December 16, 2024 |
Exhibit 99.1 News Release Edgewise Therapeutics Announces Positive Topline Results from the CANYON Phase 2 Trial of Sevasemten in Individuals with Becker Muscular Dystrophy (Becker) – Trial met primary endpoint of reduction in circulating levels of creatine kinase (CK), a biomarker associated with skeletal muscle damage, in the largest Becker interventional trial to date – – On the key secondary e |
|
| November 14, 2024 |
EX-99.1 2 tm2426483d2ex99-1.htm EXHIBIT 99.1 EXHIBIT 99.1 AGREEMENT In accordance with Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that this Statement on Schedule 13G relating to the Common Stock of Edgewise Therapeutics, Inc. is being filed with the Securities and Exchange Commission on behalf of each of them. November 14, 2024 BAKER BROS. |
|
| November 14, 2024 |
EWTX / Edgewise Therapeutics, Inc. / Flynn James E Passive Investment SC 13G/A 1 e664013sc13ga-edgewise.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 3)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) Sept |
|
| November 14, 2024 |
EWTX / Edgewise Therapeutics, Inc. / BAKER BROS. ADVISORS LP - SC 13G Passive Investment SC 13G 1 tm2426483d2sc13g.htm SC 13G SCHEDULE 13G SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 Under the Securities Exchange Act of 1934 (Amendment No. )* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28036F105 (CUSIP Number) September 30, 2024 (Date of Event which Requires Filing of this Statement) Check the approp |
|
| November 14, 2024 |
EWTX / Edgewise Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment SC 13G/A 1 ewtx13ga1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F105 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the ap |
|
| November 14, 2024 |
EWTX / Edgewise Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2411142813ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 4) Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title |
|
| November 12, 2024 |
EWTX / Edgewise Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 3 Activist Investment SC 13D/A 1 ss4110271sc13da.htm AMENDMENT NO. 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 |
|
| November 12, 2024 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 3 to the Statement on Schedule 13D, dated November 7, 2024, with respect to the common stock of Edgewise Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, as amended. Each of the undersigned agrees to be res |
|
| November 7, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Edgewise Therapeutics, Inc. |
|
| November 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 7, 2024 |
As filed with the Securities and Exchange Commission on November 7, 2024 As filed with the Securities and Exchange Commission on November 7, 2024 Registration No. |
|
| November 7, 2024 |
Exhibit 99.1 News Release Edgewise Therapeutics Reports Third Quarter 2024 Financial Results and Recent Business Highlights – On track to announce top-line results from Phase 2 CANYON trial of sevasemten in adults with Becker in December 2024 – – Advanced Phase 2 LYNX and FOX trials of sevasemten in children and adolescents with Duchenne – – Advanced Phase 2 CIRRUS-HCM trial of EDG-7500 in patient |
|
| November 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 7, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commi |
|
| November 7, 2024 |
Exhibit 10.2 [***] Portions of this exhibit have been redacted in compliance with Regulation S-K Item 601(a)(6) EDGEWISE THERAPEUTICS, INC. NOTICE OF STOCK OPTION GRANT Alan Russell (Name) [***] (Address) [***] (Address) You (the “Optionee”) have been granted an option (the “Option”) to purchase Common Stock of Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”) as follows. This Op |
|
| September 23, 2024 |
EWTX / Edgewise Therapeutics, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A 1 d894517dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 5)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denm |
|
| August 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of report (Date of earliest event reported): August 10, 2024 EDGEWISE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commi |
|
| August 12, 2024 |
Exhibit 10.1 EDGEWISE THERAPEUTICS, INC. 2024 INDUCEMENT EQUITY INCENTIVE PLAN 1. Purpose of the Plan; Award Types. 1.1 Purpose of the Plan. The purpose of this Plan is to attract and retain the best available personnel for positions of substantial responsibility by providing an inducement material to individuals entering into employment with the Company or any Parent or Subs |
|
| August 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| August 8, 2024 |
Amended and Restated Certificate of Incorporation of the Registrant Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDGEWISE THERAPEUTICS, INC. a Delaware corporation Edgewise Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Company”), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on May |
|
| August 8, 2024 |
Exhibit 99.1 News Release Edgewise Therapeutics Reports Second Quarter 2024 Financial Results and Recent Business Highlights – Completed Phase 1 SAD and MAD trial of EDG-7500 in healthy volunteers; Dosing patients in Phase 2 CIRRUS-HCM trial of EDG-7500 in individuals with oHCM – – Continued to advance GRAND CANYON global pivotal cohort of sevasemten in adults with Becker – – Advanced Phase 2 LYNX |
|
| August 8, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 8, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commiss |
|
| June 11, 2024 |
Exhibit 3.1 Certificate of Amendment to the AMENDED AND Restated Certificate of Incorporation of EDGEWISE THERAPEUTICS, INC. (Pursuant to Section 242 of the General Corporation Law of the State of Delaware) Edgewise Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: 1. The name of the Corporation is Edgewise Th |
|
| June 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 7, 2024 EDGEWISE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissio |
|
| May 10, 2024 |
Exhibit 4.4 EDGEWISE THERAPEUTICS, INC. INDENTURE Dated as of [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 4 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment of T |
|
| May 10, 2024 |
Exhibit 1.1 Edgewise Therapeutics, Inc. $175,000,000 Common stock SALES AGREEMENT May 10, 2024 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink Partners”), as follows: 1. Issuance a |
|
| May 10, 2024 |
Exhibit 1.2 Edgewise Therapeutics, Inc. $175,000,000 Common stock SALES AGREEMENT May 10, 2024 Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (“Leerink Partners”), as follows: 1. Issuance a |
|
| May 10, 2024 |
As filed with the Securities and Exchange Commission on May 10, 2024 As filed with the Securities and Exchange Commission on May 10, 2024 Registration No. |
|
| May 10, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Edgewise Therapeutics, Inc. |
|
| May 10, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 10, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissio |
|
| May 9, 2024 |
As filed with the Securities and Exchange Commission on May 9, 2024 As filed with the Securities and Exchange Commission on May 9, 2024 Registration No. |
|
| May 9, 2024 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.1 EDGEWISE THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as amended and restated March 18, 2024) Edgewise Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are n |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commission |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 9, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Edgewise Therapeutics, Inc. |
|
| May 9, 2024 |
Exhibit 99.1 News Release Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights – Announced positive two-year topline results of sevasemten ARCH open label trial and advanced GRAND CANYON pivotal cohort in Becker – –Positive interim topline data for DUNE trial of sevasemten in Becker – – Expanded Phase 2 LYNX trial of sevasemten in Duchenne – – Anticipat |
|
| May 7, 2024 |
Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors Exhibit 99.1 News Release Edgewise Therapeutics Appoints Arlene Morris to its Board of Directors Boulder, Colo., (May 7, 2024) – Edgewise Therapeutics, Inc., (Nasdaq: EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biote |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commission |
|
| May 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant x Filed by a party other than the Registrant ¨ Check the appropriate box: ¨ Preliminary Proxy Statement ¨ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ¨ Defin |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a party other than the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 26, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a party other than the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| April 15, 2024 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a party other than the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ⌧ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| February 22, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exa |
|
| February 22, 2024 |
Exhibit 99.1 News Release Edgewise Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights – Overenrolled CANYON and advanced the global pivotal cohort, GRAND CANYON, of EDG-5506 in Becker muscular dystrophy (Becker) – – Advanced Phase 2 LYNX trial of EDG-5506 including new cohort for boys with Duchenne muscular dystrophy (Duchenne) not currently tre |
|
| February 22, 2024 |
Exhibit 97.1 EDGEWISE THERAPEUTICS, INC. COMPENSATION RECOVERY POLICY As adopted on October 1, 2023 Edgewise Therapeutics, Inc. (the “Company”) is committed to strong corporate governance. As part of this commitment, the Company’s Board of Directors (the “Board”) has adopted this clawback policy called the Compensation Recovery Policy (the “Policy”). The Policy is intended to further the Company’s |
|
| February 22, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 22, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Comm |
|
| February 14, 2024 |
EWTX / Edgewise Therapeutics, Inc. / Deep Track Capital, LP Passive Investment SC 13G/A 1 deeptrack-ewtx123123a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F105 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2024 |
EWTX / Edgewise Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP Passive Investment SC 13G/A 1 sayw2402141113ga.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 3) Edgewise Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title |
|
| February 1, 2024 |
EWTX / Edgewise Therapeutics, Inc. / Flynn James E Passive Investment SC 13G/A 1 e619222sc13ga-edgewise.htm SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. 2)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) Janu |
|
| January 29, 2024 |
EWTX / Edgewise Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EDGEWISE THERAPEUTICS, INC. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 28036F105 (CUSIP Number) January 19, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 25, 2024 |
EX-99.1 2 ss2947877ex9901.htm JOINT FILING AGREEMENT Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that Amendment No. 2 to the Statement on Schedule 13D, dated January 23, 2024, with respect to the common stock of Edgewise Therapeutics, Inc. is filed on behalf of each of us pursuant to and in accordance with the provisions of Rule 13d-1(k) under the Securities Exchange Act of 1934, |
|
| January 25, 2024 |
EWTX / Edgewise Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 2 Activist Investment SC 13D/A 1 ss2947877sc13da.htm AMENDMENT NO. 2 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 |
|
| January 25, 2024 |
EWTX / Edgewise Therapeutics, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A 1 d690687dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 4)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denm |
|
| January 19, 2024 |
As filed with the Securities and Exchange Commission on January 19, 2024 As filed with the Securities and Exchange Commission on January 19, 2024 Registration No. |
|
| January 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commi |
|
| January 19, 2024 |
Results of Operations and Financial Condition, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 19, 2024 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commi |
|
| January 19, 2024 |
21,818,182 Shares Common stock TABLE OF CONTENTS Filed Pursuant to Rule 424(b)(5) Registration Nos. 333-264083 and 333-276595 Prospectus Supplement (To Prospectus Dated May 5, 2022) 21,818,182 Shares Common stock We are offering an aggregate of 21,818,182 shares of our common stock, par value $0.0001 per share. Our common stock is listed on the Nasdaq Global Select Market under the symbol “EWTX.” The last reported sale price |
|
| January 19, 2024 |
Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock Exhibit 99.1 News Release Edgewise Therapeutics Announces Pricing of $240 Million Underwritten Offering of Common Stock BOULDER, Colo., (January 19, 2024) - Edgewise Therapeutics, Inc. (NASDAQ: EWTX), a leading muscle disease biopharmaceutical company, today announced the pricing of an underwritten offering of 21,818,182 shares of its common stock at an offering price of $11.00 per share. Edgewise |
|
| January 19, 2024 |
Filed pursuant to Rule 424(b)(3) Registration No. 333-264083 SUPPLEMENT NO 1. DATED January 19, 2024 TO PROSPECTUS SUPPLEMENT DATED June 16, 2023 (To Prospectus Dated May 5, 2022) Edgewise Therapeutics, Inc. This Supplement No. 1 to Prospectus Supplement (this “Supplement”) supplements and amends the Prospectus Supplement dated June 16, 2023 (the “Prospectus Supplement”). This Supplement should be |
|
| January 19, 2024 |
Underwriting Agreement between the Company and Leerink Partners LLC, dated as of January 19, 2024. Exhibit 1.1 UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. 21,818,182 Shares of Common Stock Underwriting Agreement January 19, 2024 Leerink Partners LLC As Representative of the several Underwriters listed in Schedule 1 hereto c/o Leerink Partners LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Ladies and Gentlemen: Edgewise Therapeutics, Inc., a Delaware corporation (the |
|
| January 19, 2024 |
Exhibit 107.1 CALCULATION OF FILING FEE TABLES FORM S-3 (Form Type) EDGEWISE THERAPEUTICS, INC. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Title of each Class of Securities to be Registered Fee Calculation Rule Amount to be Registered Proposed Maximum Offering Price Per Share Proposed Maximum Aggregate Offering Price Fee Rate Amount of |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: |
|
| November 9, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commi |
|
| November 9, 2023 |
Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights Exhibit 99.1 Edgewise Therapeutics Reports Third Quarter 2023 Financial Results and Recent Business Highlights – Fully enrolled CANYON and now enrolling the global pivotal cohort, GRAND CANYON, of EDG-5506 in Becker muscular dystrophy (Becker) – – Expanding Phase 2 LYNX trial of EDG-5506 including new cohort for boys with Duchenne not currently treated with corticosteroids – – Initiated new Phase |
|
| August 10, 2023 |
Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights Exhibit 99.1 Edgewise Therapeutics Reports Second Quarter 2023 Financial Results and Recent Business Highlights – Announced positive 12-month topline results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (Becker) – – Advancing Phase 2 trial of EDG-5506 in Becker muscular dystrophy (Becker, CANYON), which now includes a pivotal cohort called GRAND CANYON – – Ad |
|
| August 10, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 10, 2023 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commis |
|
| August 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001- |
|
| July 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 10, 2023 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| June 28, 2023 |
EWTX / Edgewise Therapeutics Inc / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 3)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 19, 2023 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| June 16, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 15, 2023 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| June 16, 2023 |
Exhibit 1.1 Edgewise Therapeutics, Inc. $125,000,000 Common stock SALES AGREEMENT June 16, 2023 BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and Gentlemen: Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with BofA Securities, Inc. (“BofA”), as follows: 1. Issuance and Sale of Shares. The Company agrees tha |
|
| June 16, 2023 |
Up to $125,000,000 Common Stock TABLE OF CONTENTS As Filed Pursuant to Rule 424(b)(5) Registration No. 333-264083 PROSPECTUS SUPPLEMENT (To Prospectus dated May 5, 2022) Up to $125,000,000 Common Stock We have entered into a Sales Agreement, dated June 16, 2023, with BofA Securities, Inc. (BofA or the sales agent), relating to the sale of shares of our common stock, par value $0.0001 per share (the Sales Agreement), offered by |
|
| June 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 9, 2023 EDGEWISE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissio |
|
| May 11, 2023 |
As filed with the Securities and Exchange Commission on May 11, 2023 As filed with the Securities and Exchange Commission on May 11, 2023 Registration No. |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissio |
|
| May 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001 |
|
| May 11, 2023 |
Amended and Restated Outside Director Compensation Policy Exhibit 10.1 EDGEWISE THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY (as amended and restated March 2, 2023) Edgewise Therapeutics, Inc. (the “Company”) believes that the granting of equity and cash compensation to members of the Company’s Board of Directors (the “Board,” and members of the Board, “Directors”) represents an effective tool to attract, retain and reward Directors who are no |
|
| May 11, 2023 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Edgewise Therapeutics, Inc. |
|
| May 11, 2023 |
Form of Restricted Stock Unit Agreement Exhibit 10.2 EDGEWISE THERAPEUTICS, INC. 2021 EQUITY INCENTIVE PLAN RESTRICTED STOCK UNIT AGREEMENT NOTICE OF RESTRICTED STOCK UNIT GRANT Unless otherwise defined herein, the terms defined in the Edgewise Therapeutics, Inc. 2021 Equity Incentive Plan (the “Plan”) will have the same defined meanings in this Restricted Stock Unit Agreement which includes the Notice of Restricted Stock Unit Grant (th |
|
| May 11, 2023 |
Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights Exhibit 99.1 Edgewise Therapeutics Reports First Quarter 2023 Financial Results and Recent Business Highlights – Advancing Phase 2 trials of EDG-5506 in Becker muscular dystrophy (BMD, CANYON) and Duchenne muscular dystrophy (DMD, LYNX) – – Advancing exercise challenge study of EDG-5506 in Limb girdle muscular dystrophy 2I, BMD and McArdle Disease (LGMD2I/R9, BMD, McArdle, DUNE) – – Advancing IND- |
|
| April 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a party other than the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only |
|
| April 28, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ⌧ Filed by a party other than the Registrant ☐ Filed by a Party other than the Registrant Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of t |
|
| March 6, 2023 |
Exhibit 99.1 Edgewise Therapeutics Appoints Industry Veteran Jonathan C. Fox, M.D., Ph.D., FACC to its Board of Directors – President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – BOULDER, Colo.-(BUSINESS WIRE)-February 6, 2023-Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical com |
|
| March 6, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2023 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or ☐TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number: 001-40236 Edgewise Therapeutics, Inc. (Exa |
|
| February 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 23, 2023 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Comm |
|
| February 23, 2023 |
2021 Employee Stock Purchase Plan and forms of agreements thereunder Exhibit 10.5 EDGEWISE THERAPEUTICS, INC. 2021 EMPLOYEE STOCK PURCHASE PLAN (as amended December 2021) 1.Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an “employee st |
|
| February 23, 2023 |
Exhibit 99.1 Edgewise Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Business Highlights – Advancing Phase 2 trials of EDG-5506 in Becker muscular dystrophy (BMD, CANYON) and Duchenne muscular dystrophy (DMD, LYNX); Initiated Phase 2 exercise challenge trial of EDG-5506 in Limb girdle muscular dystrophy 2i (LGMD2I), BMD and McArdle’s Disease (DUNE) – – Initiate |
|
| February 23, 2023 |
Offer Letter between the Registrant and Marc Semigran, M.D. Exhibit 10.12 December 14, 2022 Marc Semigran, M.D. Re: Employment Offer Dear Dr. Semigran, This will confirm the terms under which Edgewise Therapeutics, Inc. (the “Company”) has made you an offer of employment: 1.Position. You will serve as Chief Development Officer, Cardiovascular Therapies and shall perform such duties as are ordinary, customary and necessary in such role. You will report to t |
|
| February 14, 2023 |
EWTX / Edgewise Therapeutics, Inc. / Cormorant Global Healthcare Master Fund, LP Passive Investment SC 13G/A 1 schedule13g.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate |
|
| February 14, 2023 |
EWTX / Edgewise Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm233474-11sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (the “Shar |
|
| February 14, 2023 |
EWTX / Edgewise Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment SC 13G/A 1 brhc10047898sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* (Amendment No. 2) Edgewise Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per sh |
|
| February 10, 2023 |
EWTX / Edgewise Therapeutics, Inc. / Flynn James E Passive Investment SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| February 1, 2023 |
EWTX / Edgewise Therapeutics, Inc. / U.S. Venture Partners XI, L.P. - SC 13D/A Activist Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) (Amendment No. 1) Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F105 (CUSIP Number) Dale Holladay c/o U.S. Venture Partners 14 |
|
| November 3, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 3, 2022 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commi |
|
| November 3, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 3, 2022 |
Edgewise Therapeutics Reports Third Quarter 2022 Financial Results Exhibit 99.1 Edgewise Therapeutics Reports Third Quarter 2022 Financial Results ? Announced positive 6-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD) ? ? Advancing CANYON Phase 2 trial in BMD and initiated LYNX Phase 2 trial in Duchenne muscular dystrophy (DMD) ? ? Cash, cash equivalents and marketable securities of $365 million as o |
|
| September 30, 2022 |
EWTX / Edgewise Therapeutics, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. S |
|
| September 26, 2022 |
EWTX / Edgewise Therapeutics, Inc. / EcoR1 Capital, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. ) Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F105 (CUSIP Number) September 14, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| September 23, 2022 |
EWTX / Edgewise Therapeutics, Inc. / Deep Track Capital, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| September 16, 2022 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated September 16, 2022, with respect to the common stock of Edgewise Therapeutics, Inc. |
|
| September 16, 2022 |
EWTX / Edgewise Therapeutics, Inc. / ORBIMED ADVISORS LLC - AMENDMENT NO. 1 Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 1002 |
|
| September 16, 2022 |
Edgewise Therapeutics, Inc. Lock-Up Agreement September 12, 2022 Edgewise Therapeutics, Inc. Lock-Up Agreement September 12, 2022 J.P. Morgan Securities LLC SVB Securities LLC c/o J.P. Morgan Securities LLC 560 Mission Street, 26th Floor San Francisco, CA 94105 c/o SVB Securities LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Re: Edgewise Therapeutics, Inc. - Lock-Up Agreement (this ?Lock-Up Agreement?) Ladies and Gentlemen: The undersigne |
|
| September 16, 2022 |
EWTX / Edgewise Therapeutics, Inc. / Novo Holdings A/S - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F 105 (CUSIP Number) Barbara Fiorini Due Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy |
|
| September 14, 2022 |
TABLE OF CONTENTS ?Filed Pursuant to Rule 424(b)5? ?Registration No. 333-264083?? Prospectus Supplement (To Prospectus Dated May 5, 2022) 11,627,907 Shares Common stock We are offering an aggregate of 11,627,907 shares of our common stock. Our common stock is listed on the Nasdaq Global Select Market under the symbol ?EWTX.? The last reported sale price of our common stock on September 13, 2022, w |
|
| September 14, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 13, 2022 EDGEWISE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Com |
|
| September 14, 2022 |
EX-1.1 2 tm2221772d4ex1-1.htm EXHIBIT 1.1 Exhibit 1.1 UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. 11,627,907 Shares of Common Stock Underwriting Agreement September 13, 2022 J.P. Morgan Securities LLC SVB Securities LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o SVB Securities LLC |
|
| September 13, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 7, 2022 EDGEWISE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Comm |
|
| September 13, 2022 |
Exhibit 99.1 News Release Edgewise Therapeutics Announces FDA Authorization for Phase 2 Clinical Trial of EDG-5506 for the Treatment of Duchenne Muscular Dystrophy (DMD) - Initiation of LYNX Phase 2 clinical trial in individuals with DMD expected in Q4 2022 - Boulder, Colo., (September 7, 2022) ? Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on dev |
|
| September 13, 2022 |
Exhibit 99.2 News Release Edgewise Therapeutics Announces Positive 4-Month Interim Results from the ARCH Open Label Study of EDG-5506 in Adults with Becker Muscular Dystrophy (BMD) ? Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories ? ? Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I ( |
|
| September 13, 2022 |
TABLE OF CONTENTS The information in this preliminary prospectus supplement is not complete and may be changed. |
|
| September 13, 2022 |
Exhibit 99.3 As used in this Exhibit 99.3, unless the context indicates otherwise, references to ?the Company,? ?we,? ?us,? ?our? and similar references refer to Edgewise Therapeutics, Inc. Capitalized terms used but not defined herein shall have the meanings ascribed to them in the Company?s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, filed with the Securities and Exchange |
|
| August 15, 2022 |
EWTX / Edgewise Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* EDGEWISE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F105 (CUSIP Number) August 15, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designat |
|
| August 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2022 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commiss |
|
| August 4, 2022 |
Edgewise Therapeutics Reports Second Quarter 2022 Financial Results Exhibit 99.1 Edgewise Therapeutics Reports Second Quarter 2022 Financial Results ? Announced positive 2-month interim results from the ARCH open label study of EDG-5506 in adults with Becker muscular dystrophy (BMD) ? ? Initiated Phase 2 trial in BMD; Expect to start Phase 2 trial in Duchenne muscular dystrophy (DMD) in 2022 ? ? Cash, cash equivalents and marketable securities of $248.4 million as |
|
| June 24, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 23, 2022 EDGEWISE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissi |
|
| May 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 11, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2022 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissio |
|
| May 11, 2022 |
Edgewise Therapeutics Reports First Quarter 2022 Financial Results Exhibit 99.1 Edgewise Therapeutics Reports First Quarter 2022 Financial Results ? Completed enrollment of the ARCH open label study of EDG-5506 in Becker muscular dystrophy (BMD) ? ? Enrollment initiated in Edgewise-funded Natural History Trial of BMD ? ? Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) planned to start in 2022 ? ? Cash, cash equivalents and marketable securities of $26 |
|
| May 5, 2022 |
TABLE OF CONTENTS ?As Filed Pursuant to Rule 424(b)5? ?Registration No. 333-264083? PROSPECTUS SUPPLEMENT(To Prospectus dated May 5, 2022) ? $125,000,000 Common Stock We have entered into a Sales Agreement (Sales Agreement) with Cowen and Company, LLC (Cowen) relating to the sale of shares of our common stock, par value $0.0001 per share, offered by this prospectus supplement and the accompanying |
|
| May 3, 2022 |
Edgewise Therapeutics, Inc. 3415 Colorado Ave Boulder, Colorado 80303 May 3, 2022 Edgewise Therapeutics, Inc. 3415 Colorado Ave Boulder, Colorado 80303 May 3, 2022 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Edgewise Therapeutics, Inc. Registration Statement on Form S-3 Filed April 1, 2022 File No. 333-264083 Acceleration Request Requested Date: May 5, 2022 Requested Time: 4:00 p.m. Eastern Time, or |
|
| May 2, 2022 |
Table of Contents ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 2, 2022 |
? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) ? ? Filed by the Registrant ? Filed by a party other than the Registrant ? ? ? Filed by a Party other than the Registrant ? ? Check the appropriate box: ? ? Preliminary Proxy Statement ? Confidential, for Use of t |
|
| April 1, 2022 |
Exhibit 4.5 EDGEWISE THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1 Definitions 1 Section 1.2 Other Definitions 4 Section 1.3 Incorporation by Reference of Trust Indenture Act 5 Section 1.4 Rules of Construction 5 ARTICLE II THE SECURITIES 5 Section 2.1 Issuable in Series 5 Section 2.2 Establishment |
|
| April 1, 2022 |
Exhibit 107 Calculation of Filing Fee Tables FORM S-3 (Form Type) EDGEWISE THERAPEUTICS, INC. |
|
| April 1, 2022 |
As filed with the Securities and Exchange Commission on April 1, 2022 Registration No. |
|
| April 1, 2022 |
Exhibit 1.2 Edgewise Therapeutics, Inc. $125,000,000 Common stock SALES AGREEMENT April 1, 2022 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Edgewise Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows: 1. Issuance and Sale of Shares. The Company ag |
|
| February 24, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 24, 2022 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Comm |
|
| February 24, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-8 (Form Type) Edgewise Therapeutics, Inc. |
|
| February 24, 2022 |
Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results Exhibit 99.1 Edgewise Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results ? Announced positive topline results from the EDG-5506 Phase 1b clinical trial in adults with Becker muscular dystrophy (BMD) ? ? Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) planned to start in 2022 ? ? Cash, cash equivalents and marketable securities of $281 million as of December 31, 20 |
|
| February 24, 2022 |
As filed with the Securities and Exchange Commission on February 24, 2022 As filed with the Securities and Exchange Commission on February 24, 2022 Registration No. |
|
| February 24, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| February 24, 2022 |
Exhibit 4.3 ? DESCRIPTION OF CAPITAL STOCK The following descriptions of our capital stock and certain provisions of our amended and restated certificate of incorporation and amended and restated bylaws are summaries and are qualified by reference to our amended and restated certificate of incorporation and amended and restated bylaws, copies of which are filed with the SEC as exhibits to the Annu |
|
| February 14, 2022 |
EWTX / Edgewise Therapeutics, Inc. / Cormorant Global Healthcare Master Fund, LP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) December 31, 2021 (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which |
|
| February 14, 2022 |
EWTX / Edgewise Therapeutics, Inc. / VIKING GLOBAL INVESTORS LP - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Amendment 1) INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Edgewise Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 28036F105 (C |
|
| February 14, 2022 |
EWTX / Edgewise Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* EDGEWISE THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F105 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Edgewise Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 28036F1 |
|
| January 13, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Edgewise Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (the “Shares”) (Title of Class of Securities) 28036F |
|
| January 13, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Edgewise Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the und |
|
| January 5, 2022 |
Exhibit 99.1 Edgewise Therapeutics Announces Positive Topline Results From the EDG-5506 Phase 1b Clinical Trial in Adults With Becker Muscular Dystrophy (BMD) ? EDG-5506 was well tolerated with no serious adverse events observed ? ? Pharmacokinetic (PK) data demonstrated robust target engagement with achievement of muscle concentrations beyond levels predicted to provide meaningful clinical benefi |
|
| January 5, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 5, 2022 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commis |
|
| November 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 10, 2021 |
Edgewise Therapeutics Reports Third Quarter 2021 Financial Results Exhibit 99.1 Edgewise Therapeutics Reports Third Quarter 2021 Financial Results ? Announced positive topline results from the EDG-5506 Phase 1 multiple ascending dose (MAD) study in healthy volunteers (HV) ? ? Dosed first Becker muscular dystrophy (BMD) patients with EDG-5506 as part of the ongoing Phase 1b trial ? ? Phase 2 trials in BMD and Duchenne muscular dystrophy (DMD) expected to start in |
|
| November 10, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2021 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Comm |
|
| October 28, 2021 |
Exhibit 99.1 Edgewise Therapeutics Announces Positive Topline Results from the EDG-5506 Phase 1 Multiple Ascending Dose (MAD) Study in Healthy Volunteers (HVs) and Doses First Becker Muscular Dystrophy (BMD) Patients ? EDG-5506 was generally well tolerated with no serious adverse events observed to date ? ? Pharmacokinetic (PK) data demonstrated robust target engagement with achievement of muscle |
|
| October 28, 2021 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 28, 2021 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commi |
|
| August 9, 2021 |
Edgewise Therapeutics Reports Second Quarter 2021 Financial Results Exhibit 99.1 Edgewise Therapeutics Reports Second Quarter 2021 Financial Results ? Continued to advance a Phase 1 MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber breakdown in Duchenne and Becker muscular dystrophy (DMD and BMD) ? ? Cash and marketable securities of $299 million as of June 30, 2021 ? BOULDER, Colo.-(BUSINESS WIRE)-August 9, 2021-Edgewise Thera |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 9, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 9, 2021 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commiss |
|
| July 12, 2021 |
EWTX / Edgewise Therapeutics, Inc. / CITADEL ADVISORS LLC - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Edgewise Therapeutics, Inc. (Name of Issuer) Common stock, par value $0.0001 per share (Title of Class of Securities) 28036F105 (CUSIP Numbe |
|
| July 12, 2021 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the common stock of Edgewise Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of t |
|
| May 18, 2021 |
Exhibit 99.1 JOINT FILING AGREEMENT This Joint Filing Agreement, dated as of May 18, 2021, is by and among Cormorant Global Healthcare Master Fund, LP, Cormorant Global Healthcare GP, LLC, Cormorant Private Healthcare Fund III, LP, Cormorant Private Healthcare GP III, LLC, Cormorant Asset Management, LP and Bihua Chen (collectively, the ?Filers?). Each of the Filers may be required to file with th |
|
| May 18, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) May 13, 2021† (Date of Event which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this |
|
| May 13, 2021 |
Offer Letter between the Company and Joanne Donovan, M.D., Ph.D. ? April 12, 2021 Joanne Donovan, M.D., Ph.D. ? Re: Employment Offer Dear Dr. Donovan, This will confirm the terms under which Edgewise Therapeutics, Inc. (the ?Company?) has made you an offer of employment: 1.Position. You will serve as Chief Medical Officer and shall perform such duties as are ordinary, customary and necessary in such role. You will report to the Chief Executive Officer of the Co |
|
| May 13, 2021 |
Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights Exhibit 99.1 Edgewise Therapeutics Reports First Quarter 2021 Financial Results and Recent Highlights ? Completed successful $202.4 million Initial Public Offering (IPO); cash and marketable securities of $309.9 million as of March 31, 2021 ? ? Initiated Phase 1 MAD study of EDG-5506, a small molecule drug candidate designed to arrest muscle fiber breakdown, the hallmark of ongoing disease in Duch |
|
| May 13, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 13, 2021 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction of incorporation) (Commissio |
|
| May 13, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q Table of Contents ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| May 3, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13D INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1 (a) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 (a) Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F105 (CUSIP Number) Dale Holladay c/o U.S. Venture Partners 1460 El Camino Real, |
|
| April 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 28036F105 (CUSIP Number) OrbiMed Advisors LLC OrbiMed Capital GP VI LLC OrbiMed Genesis GP LLC OrbiMed Capital LLC 601 Lexington Avenue, 54th Floor New York, NY 10022 Telephone: (212) |
|
| April 8, 2021 |
Exhibit 1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13D, dated April 7, 2021, with respect to the common stock of Edgewise Therapeutics, Inc. |
|
| April 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G INFORMATION TO BE INCLUDED IN STATEMENTS PURSUANT TO RULES 13d- 1(b),(c) AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO 13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934* Edgewise Therapeutics, Inc. (Name of Issuer) Common stock, $0.0001 par value per share (Title of Class of Securities) 28036F105 (CUSIP Number) M |
|
| March 31, 2021 |
Edgewise Therapeutics, Inc. Lock-Up Agreement , 2021 EX-99.1 Exhibit 99.1 Edgewise Therapeutics, Inc. Lock-Up Agreement , 2021 Goldman Sachs & Co. LLC J.P. Morgan Securities LLC SVB Leerink LLC c/o Goldman Sachs & Co. LLC 200 West Street New York, NY 10282-2198 c/o J.P. Morgan Securities LLC 560 Mission Street, 26th Floor San Francisco, CA 94105 c/o SVB Leerink LLC 1301 Avenue of the Americas, 12th Floor New York, New York 10019 Re: Edgewise Therape |
|
| March 31, 2021 |
SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Edgewise Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 28036F 105 (CUSIP Number) Peter Haahr Novo Holdings A/S Tuborg Havnevej 19 Hellerup, Denmark DK-2900 +45 3527 6592 Copy to: B. Sha |
|
| March 30, 2021 |
Amended and Restated Bylaws of the Registrant. Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF EDGEWISE THERAPEUTICS, INC. (initially adopted on May 18, 2017) (as amended and restated on March 5, 2021; effective as of the closing of the company?s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETIN |
|
| March 30, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2021 Edgewise Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-40236 82-1725586 (State or other jurisdiction (Commission (IRS Employer |
|
| March 30, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDGEWISE THERAPEUTICS, INC. a Delaware corporation Edgewise Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on May |
|
| March 30, 2021 |
Exhibit 99.1 Edgewise Therapeutics Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters? Option to Purchase Additional Shares BOULDER, Colo., Mar. 30, 2021 (BUSINESS NEWSWIRE) - Edgewise Therapeutics, Inc., (NASDAQ: EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, announ |
|
| March 30, 2021 |
SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO RULES 13d-1(b)(c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(b) (Amendment No. |
|
| March 26, 2021 |
As filed with the Securities and Exchange Commission on March 26, 2021 Registration No. |
|
| March 26, 2021 |
11,000,000 shares Common stock TABLE OF CONTENTS ?Filed pursuant to Rule 424(b)(4)? ?Registration Nos. 333-253923 and 333-254739? 11,000,000 shares Common stock This is an initial public offering of shares of common stock by Edgewise Therapeutics, Inc. We are offering 11,000,000 shares of our common stock. The initial public offering price is $16.00 per share. Prior to this offering, there has been no public market for our comm |
|
| March 25, 2021 |
S-1MEF 1 tm2037601d19s1mef.htm S-1MEF As filed with the Securities and Exchange Commission on March 25, 2021. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT Under The Securities Act of 1933 EDGEWISE THERAPEUTICS, INC. (Exact name of Registrant as specified in its charter) Delaware 2834 82-1725586 (State or other jurisdi |
|
| March 24, 2021 |
Form of Underwriting Agreement. Exhibit 1.1 UNDERWRITING AGREEMENT Edgewise Therapeutics, Inc. [•] Shares of Common Stock Underwriting Agreement March [•], 2021 J.P. Morgan Securities LLC Goldman Sachs & Co. LLC SVB Leerink LLC As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, New York 10179 c/o Goldman Sachs & Co. LLC 200 West Street New York, |
|
| March 24, 2021 |
? As filed with the Securities and Exchange Commission on March 24, 2021 Registration No. |
|
| March 22, 2021 |
TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 22, 2021 Registration No. |
|
| March 22, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDGEWISE THERAPEUTICS , INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Edgewise Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: F |
|
| March 22, 2021 |
March 22, 2021 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| March 22, 2021 |
March 22, 2021 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N. |
|
| March 22, 2021 |
Specimen common stock certificate of the Registrant Exhibit 4.2 SPECIMENSPECIMEN NUMBERSHARES C-EdgEwisE ThErapEuTics, inc. This CerTifies ThaT: INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE C o M M o n s T o C K SEE REVERSE FOR CERTAIN DEFINITIONS CUSIP28036F105 SPECIMEN - NOT NEGOTIABLE is The owner of FULLY PAID AND NON-ASSESSABLE SHARES OF COMMON STOCK OF $0.0001 PAR VALUE EACH OF EdgEwisE ThErapEuTics, inc. transferable on the books of |
|
| March 22, 2021 |
2021 Employee Stock Purchase Plan and forms of agreements thereunder. ? Exhibit 10.4 ? EDGEWISE THERAPEUTICS,?INC. ? 2021?EMPLOYEE STOCK PURCHASE PLAN ?? 1.?????????????Purpose. The purpose of the Plan is to provide employees of the Company and its Designated Companies with an opportunity to purchase Common Stock through accumulated Contributions. The Company intends for the Plan to have two components: a component that is intended to qualify as an ?employee stock p |
|
| March 22, 2021 |
2021 Equity Incentive Plan and forms of agreements thereunder ? Exhibit 10.3 ?? EDGEWISE THERAPEUTICS,?INC. ? 2021 EQUITY INCENTIVE PLAN ? 1. Purposes of the Plan. The purposes of this Plan are: ? ? to attract and retain the best available personnel for positions of substantial responsibility, ? ? to provide additional incentive to Employees, Directors and Consultants, and ? ? to promote the success of the Company?s business. ? The Plan permits the grant of |
|
| March 17, 2021 |
Registration Statement on Form 8-A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 EDGEWISE THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 82-1725586 (State of incorporation or organization) (I.R.S. Employer Identification No.) 3415 Colorado Av |
|
| March 8, 2021 |
CONFIDENTIAL TREATMENT REQUESTED BY EDGEWISE THERAPEUTICS, INC. Wilson Sonsini Goodrich & Rosati Professional Corporation 650 Page Mill Road Palo Alto, California 94304-1050 o: 650. |
|
| March 5, 2021 |
Offer Letter between the Registrant and R. Michael Carruthers. Exhibit 10.8 March 3, 2021 R. Michael Carruthers c/o Edgewise Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Mr. Carruthers: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Edgewise Therapeutics, Inc. (the ?Company? or ?we?), effective as of the effective date of the Company?s registration statement relating to the Company?s initial publi |
|
| March 5, 2021 |
Exhibit 4.1 EDGEWISE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT This Amended and Restated Investors? Rights Agreement (this ?Agreement?) is made as of December 3, 2020 (the ?Effective Date?), by and among Edgewise Therapeutics, Inc., a Delaware corporation (the ?Company?), and the persons and entities listed on Exhibit A hereto (each, an ?Investor? and collectively, the ?I |
|
| March 5, 2021 |
Offer Letter between the Registrant and Behrad Derakhshan, Ph.D. Exhibit 10.9 March 3, 2021 Behrad Mokhtar-Derakhshan, Ph.D. c/o Edgewise Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Dr. Derakhshan: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Edgewise Therapeutics, Inc. (the ?Company? or ?we?), effective as of the effective date of the Company?s registration statement relating to the Company?s in |
|
| March 5, 2021 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDGEWISE THERAPEUTICS, INC. a Delaware corporation Edgewise Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on May |
|
| March 5, 2021 |
Offer Letter between the Registrant and Kevin Koch, Ph.D. Exhibit 10.5 March 3, 2021 Kevin Koch, Ph.D. c/o Edgewise Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Dr. Koch: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Edgewise Therapeutics, Inc. (the ?Company? or ?we?), effective as of the effective date of the Company?s registration statement relating to the Company?s initial public offering |
|
| March 5, 2021 |
Offer Letter between the Registrant and Alan Russell, Ph.D. Exhibit 10.6 March 3, 2021 Alan Russell, Ph.D. c/o Edgewise Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Dr. Russell: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Edgewise Therapeutics, Inc. (the ?Company? or ?we?), effective as of the effective date of the Company?s registration statement relating to the Company?s initial public off |
|
| March 5, 2021 |
Executive Incentive Compensation Plan. Exhibit 10.11 EDGEWISE THERAPEUTICS, INC. EXECUTIVE INCENTIVE COMPENSATION PLAN 1. Purposes of the Plan. The Plan is intended to increase stockholder value and the success of the Company by motivating Employees to (a) perform to the best of their abilities and (b) achieve the Company?s objectives. 2. Definitions. 2.1 ?Actual Award? means as to any Performance Period, the actual award (if any) paya |
|
| March 5, 2021 |
Offer Letter between the Registrant and John Moore. Exhibit 10.10 March 3, 2021 John Moore c/o Edgewise Therapeutics, Inc. Re: Confirmatory Employment Letter Dear Mr. Moore: This confirmatory employment letter agreement (the ?Agreement?) is entered into between you and Edgewise Therapeutics, Inc. (the ?Company? or ?we?), effective as of the effective date of the Company?s registration statement relating to the Company?s initial public offering (the |
|
| March 5, 2021 |
2017 Equity Incentive Plan, as amended, and forms of agreement thereunder. Exhibit 10.2 EDGEWISE THERAPEUTICS, INC. 2017 EQUITY INCENTIVE PLAN As Adopted by the Board and Stockholders on June 5, 2017 Amended by the Board and Stockholders as of November 30, 2020 1.??? ???????PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, its P |
|
| March 5, 2021 |
Lease between the Registrant and Regents of the University of Colorado, dated July 21, 2020. EX-10.14 17 tm2037601d8ex10-14.htm EXHIBIT 10.14 Exhibit 10.14 LEASE FOR PREMISES LOCATED AT JENNIE SMOLY CARUTHERS BIOTECHNOLOGY BUILDING UNIVERSITY OF COLORADO BOULDER 3415 COLORADO AVENUE, BOULDER, COLORADO 80309 BY AND BETWEEN EDGEWISE THERAPEUTICS, INC., A DELAWARE CORPORATION AS TENANT AND THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE AS LANDLORD TABLE OF CONTENTS PAGE ARTICLE |
|
| March 5, 2021 |
Amended and Restated Certificate of Incorporation of the Registrant, as currently in effect. Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDGEWISE THERAPEUTICS , INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Edgewise Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: F |
|
| March 5, 2021 |
Executive Change in Control and Severance Plan. Exhibit 10.12 EDGEWISE THERAPEUTICS, INC. EXECUTIVE CHANGE IN CONTROL AND SEVERANCE PLAN AND SUMMARY PLAN DESCRIPTION 1.???????????Introduction. The purpose of this Edgewise Therapeutics, Inc. Executive Change in Control and Severance Plan (the ?Plan?) is to provide assurances of specified benefits to certain employees of the Company whose employment could be being involuntarily terminated other t |
|
| March 5, 2021 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF EDGEWISE THERAPEUTICS, INC. (initially adopted on May 18, 2017) (as amended and restated on , 2021; effective as of the closing of the company?s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2.2 ANNUAL MEETING 1 2.3 |
|
| March 5, 2021 |
Bylaws of the Registrant, as currently in effect. Exhibit 3.3 BYLAWS OF EDGEWISE THERAPEUTICS, INC. ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have of |
|
| March 5, 2021 |
Exhibit 10.1 EDGEWISE THERAPEUTICS, INC. INDEMNIFICATION AGREEMENT This Indemnification Agreement (this ?Agreement?) is dated as of [ , 20], and is between Edgewise Therapeutics, Inc., a Delaware corporation (the ?Company?), and [] (?Indemnitee?). RECITALS A.????????????Indemnitee?s service to the Company substantially benefits the Company. B.?????????????Individuals are reluctant to serve as dire |
|
| March 5, 2021 |
Outside Director Compensation Policy. Exhibit 10.13 EDGEWISE THERAPEUTICS, INC. OUTSIDE DIRECTOR COMPENSATION POLICY Edgewise Therapeutics, Inc. (the ?Company?) believes that the granting of equity and cash compensation to members of the Company?s Board of Directors (the ?Board,? and members of the Board, ?Directors?) represents an effective tool to attract, retain and reward Directors who are not employees of the Company (?Outside Di |
|
| March 5, 2021 |
Power of Attorney (see page II-6 to Form S-1 filed with the SEC on March 5, 2021). TABLE OF CONTENTS As filed with the Securities and Exchange Commission on March 5, 2021 Registration No. |
|
| March 2, 2021 |
Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDGEWISE THERAPEUTICS, INC. a Delaware corporation Edgewise Therapeutics, Inc., a corporation organized and existing under the laws of the State of Delaware (the ?Company?), does hereby certify as follows: A. The original Certificate of Incorporation of the Company was filed with the Secretary of State of the State of Delaware on May |
|
| March 2, 2021 |
Exhibit 10.2 EDGEWISE THERAPEUTICS, INC. 2017 EQUITY INCENTIVE PLAN As Adopted by the Board and Stockholders on June 5, 2017 Amended by the Board and Stockholders as of November 30, 2020 1.??? ???????PURPOSE. The purpose of this Plan is to provide incentives to attract, retain and motivate eligible persons whose present and potential contributions are important to the success of the Company, its P |
|
| March 2, 2021 |
TABLE OF CONTENTS Amendment No. 2 to Draft Registration Statement, as confidentially submitted to the Securities and Exchange Commission on March 1, 2021. This Draft Registration Statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- ? ? ? UNITED STATES SECURITIES AND EXCHANGE COMMISSION Was |
|
| March 2, 2021 |
EX-3.4 3 filename3.htm Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF EDGEWISE THERAPEUTICS, INC. (initially adopted on May 18, 2017) (as amended and restated on , 2021; effective as of the closing of the company’s initial public offering) TABLE OF CONTENTS Page ARTICLE I - CORPORATE OFFICES 1 1.1 REGISTERED OFFICE 1 1.2 OTHER OFFICES 1 ARTICLE II - MEETINGS OF STOCKHOLDERS 1 2.1 PLACE OF MEETINGS 1 2 |
|
| January 25, 2021 |
DRS/A 1 filename1.htm TABLE OF CONTENTS Amendment No. 1 to Draft Registration Statement, as confidentially submitted to the Securities and Exchange Commission on January 22, 2021. This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCH |
|
| January 22, 2021 |
650 Page Mill Road Palo Alto, CA 94304-1050 650.493.9300 650.493.6811 www.wsgr.com January 22, 2021 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tracey Houser Kevin Vaughn Courtney Lindsay Celeste Murphy Re: Edgewise Therapeutics, Inc. Draft Registration Statement on Form S-1 Conf |
|
| December 18, 2020 |
EDGEWISE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.1 EDGEWISE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT This Amended and Restated Investors? Rights Agreement (this ?Agreement?) is made as of December 3, 2020 (the ?Effective Date?), by and among Edgewise Therapeutics, Inc., a Delaware corporation (the ?Company?), and the persons and entities listed on Exhibit A hereto (each, an ?Investor? and collectively, the ?I |
|
| December 18, 2020 |
Exhibit 10.10 LEASE FOR PREMISES LOCATED AT JENNIE SMOLY CARUTHERS BIOTECHNOLOGY BUILDING UNIVERSITY OF COLORADO BOULDER 3415 COLORADO AVENUE, BOULDER, COLORADO 80309 BY AND BETWEEN EDGEWISE THERAPEUTICS, INC., A DELAWARE CORPORATION AS TENANT AND THE REGENTS OF THE UNIVERSITY OF COLORADO, A BODY CORPORATE AS LANDLORD TABLE OF CONTENTS PAGE ARTICLE 1. ? DEFINITIONS AND BASIC LEASE PROVISIONS 1 1.1 |
|
| December 18, 2020 |
TABLE OF CONTENTS As confidentially submitted to the Securities and Exchange Commission on December 18, 2020 This draft registration statement has not been filed publicly with the Securities and Exchange Commission, and all information herein remains strictly confidential. |
|
| December 18, 2020 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF EDGEWISE THERAPEUTICS , INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Edgewise Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIFY: F |
|
| December 18, 2020 |
BYLAWS EDGEWISE THERAPEUTICS, INC. ARTICLE I Offices Exhibit 3.3 BYLAWS OF EDGEWISE THERAPEUTICS, INC. ARTICLE I Offices Section 1. Registered Office. The registered office of the corporation in the State of Delaware shall be in the City of Dover, County of Kent. Section 2. Other Offices. The corporation shall also have and maintain an office or principal place of business at such place as may be fixed by the Board of Directors, and may also have of |
